Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) ended Wednesday session in red amid volatile trading. The shares closed down -0.005 points or -0.90% at $0.505 with 402,536 shares getting traded. Post opening the session at $0.53, the shares hit an intraday low of $0.50 and an intraday high of $0.53 and the price vacillated in this range throughout the day.
Market Cap/Outstanding Shares
The company has a market cap of $63.66 million and the number of outstanding shares have been calculated to be 123.69 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at -12.46%, resulting in a performance for the month at 14.25%. Therefore, the stated figure displays a quarterly performance of 50.52% and an annual performance of -89.69% traded down -0.90% on 30 November, 2016 hitting $0.505.
Beta factor is stands at 1.82 and Avg. true range is 0.06. Historically, the volatility of this stock is about 8.39% a week and 11.62% a month.
Northwest Biotherapeutics, Inc (NWBO) recently joined the University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany in announcing a Phase II clinical trial program combining DCVax®-L and Pembrolizumab (Keytruda®) for colorectal cancer with liver metastases.
The trial will be conducted as an investigator-initiated trial led by the University of Mainz, thereby substantially reducing the costs involved. NW Bio will provide the DCVax-L products and MSD Sharp & Dohme GmbH will provide the Pembrolizumab. (MSD Sharp & Dohme is the operating name used by U.S.-based Merck & Co., Inc. outside the U.S. and Canada.) All of the parties contributed to and approved the novel trial design.
This trial will combine a broad spectrum personalized vaccine (DCVax®-L) with a highly targeted checkpoint inhibitor drug (Pembrolizumab). In contrast, most combination trials to date have combined two specifically targeted agents, with no broad spectrum agent included.
Colorectal cancer represents a major unmet medical need. The number of new cases per year is second only to lung cancer, and colorectal cancer results in about 700,000 deaths per year in the Western world. Colorectal cancer is very heterogeneous and various therapies to date, counting various immune therapies when used as a single agent, have been disappointing.